Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology
-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the
-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --
-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --

(Photo: Business Wire)
“This acquisition marks a transformational step for Cosette, adding patented, high-growth products to solidify our leadership in women’s health in the
“Joining the Cosette team amplifies our shared mission to improve lives through innovative and accessible Women’s health and dermatology medicines,” said Shawn Patrick O’Brien, CEO, Mayne Pharma. “This transaction represents a unique opportunity for our employees, customers, and patients. Together, we will extend the reach of important therapies, drive innovation, and improve patient access.”
Transaction Rationale
-
Strengthens Cosette’s dermatology and women’s health businesses
The combination will create a leading women’s health and dermatology focused pharmaceuticals company in theU.S. with an established presence in international markets, utilizing the strengths of two industry players to drive innovation and expand access to women’s health therapies.
-
Expands Cosette’s commercial and operational capabilities
Cosette will utilize its market-leading commercial and operational capabilities, backed by its 350+ strong team and a leading portfolio of women’s health and dermatology products alongside Mayne Pharma’s complementary strength in these specialty areas. Mayne Pharma is backed by a 480+ strong team, including highly effective and successful sales and marketing teams in both specialties. The combined company will have two state-of-the-art FDA -approved manufacturing sites – one each inLincolnton, North Carolina andSalisbury ,South Australia – to service patients globally.
-
Adds multiple sustainable and growing patent-protected products
Upon close, Cosette will market 12 patent-protected products focused on women’s health and dermatology, including leading brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®, and several programs in clinical development.
Terms of the Transaction
The transaction, which comprises the acquisition of
Cosette is being advised by Santander US Capital Markets LLC and UBS Investment Bank as financial advisers and Ropes & Gray LLP and Corrs Chambers Westgarth as legal advisers.
Mayne Pharma is being advised by Jefferies Australia as financial adviser and Gilbert + Tobin and Arnold & Porter as legal advisers.
About Cosette Pharmaceuticals
Cosette Pharmaceuticals, Inc. is a
VYLEESI®, CLOMID®, INTRAROSA®, AMBIEN®, AMBIEN® CR, WELCHOL®, AZOR®, TRIBENZOR®, BENICAR®, BENICAR® HCT, EFFIENT®, EVOXAC®, ANUCORT-HC®, PROMETHEGAN®, and MIGERGOT® are trademarks of Cosette Pharmaceuticals, Inc.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma has a 40- year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit Maynepharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220569463/en/
Cosette Pharmaceuticals:
Media:
media@cosettepharma.com
Source: Cosette Pharmaceuticals, Inc.